Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Nektar Therapeutics (NKTR) had Weighted-Average Shares Outstanding (Diluted) of 14.09M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$11.18M |
|
$-41.59M |
|
-- |
|
$11.18M |
|
$47.41M |
|
$-36.23M |
|
$-3.17M |
|
$-39.40M |
|
$-39.40M |
|
$-39.21M |
|
$-41.59M |
|
$-41.59M |
|
$-39.21M |
|
$-36.23M |
|
$-36.88M |
|
14.09M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
14.09M |
$-2.95 |
|
$-2.95 |
|
| Balance Sheet Financials | |
$186.57M |
|
$2.99M |
|
$20.97M |
|
$207.53M |
|
$71.39M |
|
-- |
|
$160.35M |
|
$231.75M |
|
$-24.21M |
|
$-24.21M |
|
$-24.21M |
|
12.46M |
|
| Cash Flow Statement Financials | |
$-94.79M |
|
$93.30M |
|
$0.22M |
|
$44.25M |
|
$42.99M |
|
$-1.26M |
|
$7.38M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.61 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-324.21% |
|
-324.21% |
|
-- |
|
-352.53% |
|
-372.20% |
|
$-94.83M |
|
-- |
|
-- |
|
-- |
|
0.05 |
|
-- |
|
-- |
|
-- |
|
171.79% |
|
171.79% |
|
-20.04% |
|
171.79% |
|
$-1.94 |
|
$-6.73 |
|
$-6.73 |
|